Industry News

Alliance Formed To Discover and Develop Therapeutic Monoclonal Antibodies

Published in Vaccine Weekly, April 5th, 2000

Corixa Corp., Seattle, Washington, announced a collaboration with Abgenix, Inc. to discover and develop human monoclonal antibodies against selected targets from Corixa's library of proprietary autoimmune disease, cancer, and infectious disease antigens.

Under the terms of the agreement, Corixa will contribute three targets initially and up to six targets a year during the six-year agreement. Abgenix will contribute its XenoMouse technology to the collaboration to generate, screen, and characterize human monoclonal antibodies directed against Corixa's antigens. Corixa, and in some cases Abgenix, will then be responsible for determining whether the characterized...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry